GLR 2007
Alternative Names: GLR2007; GLR2007-237FALatest Information Update: 31 Aug 2023
Price :
$50 *
At a glance
- Originator Gan&Lee Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Glioblastoma; Non-small cell lung cancer
- Phase I Solid tumours
Most Recent Events
- 22 Aug 2023 Phase-I clinical trials in Solid tumours in China (unspecified route) (Gan&Lee Pharmaceuticals pipeline, August 2023)
- 29 Jul 2022 Gan&Lee Pharmaceuticals completes a phase I/II trial in Glioblastoma (In adults, In the elderly, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO) (NCT04444427)
- 29 Jul 2022 Gan&Lee Pharmaceuticals completes a phase I/II trial in Non-small cell lung cancer (In adults, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT04444427)